X4 Pharmaceuticals Inc(XFOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XFOR X4 Pharmaceuticals Inc

Post-Mkt 01-09 16:40:05 EST

4.00

-0.04

-0.99%

盘后4.05

+0.05+1.25%

16:21 EST

High4.24	Low3.98	Vol1.09M
Open4.14	D1 Closing4.04	Amplitude6.44%
Mkt Cap349.75M	Tradable Cap278.20M	Total Shares87.44M
T/O4.50M	T/O Rate1.57%	Tradable Shares69.55M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XFOR","market":"US","secType":"STK","nameCN":"X4 Pharmaceuticals Inc","latestPrice":4,"timestamp":1767992400000,"preClose":4.04,"halted":0,"volume":1089034,"hourTrading":{"tag":"盘后","latestPrice":4.05,"preClose":4,"latestTime":"16:21 EST","volume":1750,"amount":7000.150499999999,"timestamp":1767993687038},"delay":0,"floatShares":69550600,"shares":87436700,"eps":-10.5034,"marketStatus":"Post-Mkt","change":-0.04,"latestTime":"01-09 16:40:05 EST","open":4.14,"high":4.24,"low":3.98,"amount":4501731.641276,"amplitude":0.064356,"askPrice":4.05,"askSize":100,"bidPrice":3.95,"bidSize":114,"shortable":3,"etf":0,"ttmEps":-10.5034,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1768006800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1510808400000,"exchange":"NASDAQ","adjPreClose":4.04,"preHourTrading":{"tag":"盘前","latestPrice":4.11,"preClose":4.04,"latestTime":"09:26 EST","volume":4062,"amount":16894.865375999998,"timestamp":1767968772399},"postHourTrading":{"tag":"盘后","latestPrice":4.05,"preClose":4,"latestTime":"16:21 EST","volume":1750,"amount":7000.150499999999,"timestamp":1767993687038},"volumeRatio":3.344083,"impliedVol":0.72,"impliedVolPercentile":0.6351},"requestUrl":"/m/hq/s/XFOR","defaultTab":"news","newsList":[{"id":"2593472213","title":"X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Shares May Have Run Too Fast Too Soon","url":"https://stock-news.laohu8.com/highlight/detail?id=2593472213","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593472213?lang=en_us&edition=fundamental","pubTime":"2025-12-24 18:22","pubTimestamp":1766571731,"startTime":"0","endTime":"0","summary":"With a median price-to-sales (or \"P/S\") ratio of close to 12.4x in the Biotechs industry in the United States, you...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xfor/x4-pharmaceuticals/news/x4-pharmaceuticals-incs-nasdaqxfor-shares-may-have-run-too-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xfor/x4-pharmaceuticals/news/x4-pharmaceuticals-incs-nasdaqxfor-shares-may-have-run-too-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QID","QLD","XFOR","SQQQ","NVIW.SI","BK4139","PSQ","TQQQ","TSYW.SI","MNQmain",".IXIC","USAW.SI","NQmain","USJW.SI"],"gpt_icon":1},{"id":"2582875432","title":"X4 Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2582875432","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582875432?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:18","pubTimestamp":1762777080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XFOR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 10, 2025 07:18 ET (12:18 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2581709981","title":"X4 Pharmaceuticals to Join Guggenheim Healthcare Innovation Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2581709981","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581709981?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:01","pubTimestamp":1762376472,"startTime":"0","endTime":"0","summary":"X4 Pharmaceuticals will participate in the Guggenheim Second Annual Healthcare Innovation Conference, taking place in Boston from November 10-12, 2025. The company will hold a fireside chat on November 10 at 8:30 a.m. ET and be available for one-on-one meetings with investors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. X4 Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on November 05, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL3kJSsj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU0314104364.USD","NDAQ","BK4112","XFOR","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210149790.SGD","IE00BKPKM429.USD","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"2581156724","title":"X4 Pharma Q3 net loss narrows to $29.8 mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2581156724","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581156724?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:23","pubTimestamp":1762345412,"startTime":"0","endTime":"0","summary":"X4 Pharma Q3 net loss narrows to $29.8 mlnOverviewX4 Pharmaceuticals Q3 net loss narrows to $29.8 mln from $36.7 mln yr agoCompany raised $240.3 mln in financing, extending cash runway to end of 2028X","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL1N3WH0LH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XFOR","BK4139"],"gpt_icon":0},{"id":"2581297617","title":"X4 Pharmaceuticals Reports $240 Million Financing and Shifts Focus to Phase 3 Chronic Neutropenia Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2581297617","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581297617?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:00","pubTimestamp":1762344023,"startTime":"0","endTime":"0","summary":"X4 Pharmaceuticals Inc. reported its third quarter 2025 financial results and provided a corporate update. The company announced a strategic shift, prioritizing the advancement of the 4WARD Phase 3 pivotal trial of mavorixafor in patients with moderate and severe chronic neutropenia. As part of its restructuring efforts since August, X4 implemented a 50% workforce reduction, resulting in approximately $13 million in annualized cost savings. The company has also increased the enrollment target for the 4WARD study to 176 patients, with enrollment now expected to be completed in the third quarter of 2026. X4 deprioritized the commercialization of mavorixafor  for WHIM syndrome, while maintaining patient access. The company completed two financial transactions totaling $240.3 million in gross proceeds, extending its cash runway to the end of 2028. X4 expects this financial position to support the completion of the 4WARD trial, a potential sNDA filing for the chronic neutropenia indication,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDLJHcD3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","NDAQ","LU2095319765.USD","BK4139","LU0314104364.USD","IE00B64PRP62.GBP","BK4112","IE00BGHQF748.EUR","LU2210149790.SGD","XFOR","LU2210150020.SGD","IE00BKPKM429.USD","BK4585","BK4588"],"gpt_icon":0},{"id":"2581729709","title":"X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2581729709","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581729709?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:00","pubTimestamp":1762344008,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUA3SPXQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2578167761","title":"X4 Pharmaceuticals Raises $155.3 Million in Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2578167761","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578167761?lang=en_us&edition=fundamental","pubTime":"2025-10-28 07:05","pubTimestamp":1761606339,"startTime":"0","endTime":"0","summary":"X4 Pharmaceuticals Inc. announced the closing of an underwritten public offering, raising approximately $155.3 million in gross proceeds. The offering included 52,844,000 shares of common stock, as well as pre-funded warrants to purchase up to 700,000 shares. The underwriters exercised their option to purchase an additional 6,984,000 shares in full. The shares were offered at $2.90 per share, and the pre-funded warrants at $2.899 per warrant with an exercise price of $0.001 per share. After the offering, the total shares outstanding stood at 79,214,708. Leerink Partners, Stifel, and Guggenheim Securities acted as joint bookrunning managers for the offering.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. X4 Pharmaceuticals Inc. publishe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nNDL8nBl3C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4207","IE00B3QW5Z07.USD","BK4127","LU0314104364.USD","BK4585","LU2095319765.USD","LU2210150020.SGD","IE00B64PRP62.GBP","XFOR","BK4588","LU2210149790.SGD","BK4139","MNSH","NDAQ","SF","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112"],"gpt_icon":0},{"id":"2578721066","title":"X4 Pharmaceuticals Executive Chairman Adam R. Craig Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2578721066","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578721066?lang=en_us&edition=fundamental","pubTime":"2025-10-28 06:41","pubTimestamp":1761604878,"startTime":"0","endTime":"0","summary":"Adam R. Craig, Executive Chairman of X4 Pharmaceuticals Inc., has reported the acquisition of common shares of the company, according to a recent SEC filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. X4 Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 27, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nNDL1tHSgP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2577636511","title":"BUZZ-U.S. STOCKS ON THE MOVE-Cipher Mining, Kura, GrafTech","url":"https://stock-news.laohu8.com/highlight/detail?id=2577636511","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577636511?lang=en_us&edition=fundamental","pubTime":"2025-10-24 21:11","pubTimestamp":1761311480,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Cipher Mining, Kura, GrafTechEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: http","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nL6N3W50JA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WU","BK4161","CIFR","COYA","BAH","LU0006306889.USD","LU0690374961.EUR","LU1244550577.SGD","MHK","INSP","LU0061474960.USD","PG","LU0683600562.USD","NIC","LU1868837300.USD","LU0690374615.EUR","KURA","MOFG","LU1861558580.USD","HL","HUT","DECK","IE00BWXC8680.SGD","LU1951200564.SGD","LU0345770993.USD","XFOR","TDOC","HCA","STX","IE00BKVL7J92.USD","EAF","LU1951198990.SGD","LU2242646821.SGD","GD","LU1206713676.USD","IE00BLSP4239.USD","CL","IE00B19Z9505.USD","QLGN","CDE","LU0345769631.USD","LU0345780521.USD","ITW","LU0477156953.USD","F","ALK"],"gpt_icon":1},{"id":"2577565856","title":"X4 Pharmaceuticals Prices $135 Million Public Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2577565856","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577565856?lang=en_us&edition=fundamental","pubTime":"2025-10-24 12:38","pubTimestamp":1761280690,"startTime":"0","endTime":"0","summary":"X4 Pharmaceuticals Inc. has announced the pricing of an underwritten public offering, raising approximately $135 million through the issuance of 45,860,000 shares of common stock at $2.90 per share and pre-funded warrants to purchase up to 700,000 shares at $2.899 per warrant. The pre-funded warrants are exercisable immediately at an exercise price of $0.001 per share. The company has also granted underwriters a 30-day option to purchase up to an additional 6,984,000 shares. X4 intends to use the proceeds to fund the Phase 3 development of mavorixafor for chronic neutropenic disorders, as well as for general corporate purposes. Leerink Partners, Stifel, and Guggenheim Securities are acting as joint bookrunning managers for the offering.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDL3ZZRXT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","LU2210150020.SGD","BK4139","BK4112","LU2210149790.SGD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4588","LU0314104364.USD","MNSH","SF","BK4585","NDAQ","IE00BKPKM429.USD","BK4207","XFOR"],"gpt_icon":0},{"id":"2577856583","title":"X4 Pharmaceuticals Inc - Prices Public Offering at $2.90 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2577856583","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577856583?lang=en_us&edition=fundamental","pubTime":"2025-10-24 12:37","pubTimestamp":1761280677,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nTUA3MSMSB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XFOR","BK4139"],"gpt_icon":0},{"id":"2577831565","title":"X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2577831565","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577831565?lang=en_us&edition=fundamental","pubTime":"2025-10-24 12:37","pubTimestamp":1761280677,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nTUA3MSMSB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2577353051","title":"BRIEF-X4 Pharmaceuticals Announces Proposed Underwritten Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2577353051","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577353051?lang=en_us&edition=fundamental","pubTime":"2025-10-24 06:36","pubTimestamp":1761259018,"startTime":"0","endTime":"0","summary":"BRIEF-X4 Pharmaceuticals Announces Proposed Underwritten Public OfferingX4 Pharmaceuticals Inc XFOR.O:X4 PHARMACEUTICALS ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERINGX4 PHARMACEUTICALS INC - PROCEED","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nTUA1LTMLM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2577851536","title":"X4 Pharmaceuticals Inc - Proceeds  to Fund Phase 3 Development of Mavorixafor","url":"https://stock-news.laohu8.com/highlight/detail?id=2577851536","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577851536?lang=en_us&edition=fundamental","pubTime":"2025-10-24 04:01","pubTimestamp":1761249660,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nTUA1LTMLM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XFOR","BK4139"],"gpt_icon":0},{"id":"2568982664","title":"X4 Pharmaceuticals announces restructuring, 50% reduction in workforce","url":"https://stock-news.laohu8.com/highlight/detail?id=2568982664","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568982664?lang=en_us&edition=fundamental","pubTime":"2025-09-17 19:10","pubTimestamp":1758107446,"startTime":"0","endTime":"0","summary":"X4 Pharmaceuticals (XFOR) announced a strategic restructuring designed to sharpen operational focus and align resources with the Company’s long-ter...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/x4-pharmaceuticals-announces-restructuring-50-reduction-in-workforce-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/x4-pharmaceuticals-announces-restructuring-50-reduction-in-workforce-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2568498307","title":"X4 Pharmaceuticals - John Volpone Appointed COO in Addition to Current Role as President","url":"https://stock-news.laohu8.com/highlight/detail?id=2568498307","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568498307?lang=en_us&edition=fundamental","pubTime":"2025-09-17 19:00","pubTimestamp":1758106800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250917:nTUA8M3GRH:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XFOR","BK4139"],"gpt_icon":0},{"id":"2568498302","title":"X4 Pharmaceuticals: as Part of Workforce Reduction, Mary Dibiase, Chief Operating Officer Will Be Exiting Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2568498302","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568498302?lang=en_us&edition=fundamental","pubTime":"2025-09-17 19:00","pubTimestamp":1758106800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250917:nTUA8M3GRH:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XFOR","BK4139"],"gpt_icon":0},{"id":"2568460742","title":"X4 Pharmaceuticals Inc - to Cut Workforce by 50%, Save $13 Mln Annually","url":"https://stock-news.laohu8.com/highlight/detail?id=2568460742","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568460742?lang=en_us&edition=fundamental","pubTime":"2025-09-17 19:00","pubTimestamp":1758106800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250917:nTUA8M3GRH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XFOR","BK4139"],"gpt_icon":0},{"id":"2568460068","title":"X4 Pharmaceuticals Inc - Three Executives to Exit X4 Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2568460068","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568460068?lang=en_us&edition=fundamental","pubTime":"2025-09-17 19:00","pubTimestamp":1758106800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250917:nTUA8M3GRH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XFOR"],"gpt_icon":0},{"id":"2568460044","title":"Press Release: X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation","url":"https://stock-news.laohu8.com/highlight/detail?id=2568460044","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568460044?lang=en_us&edition=fundamental","pubTime":"2025-09-17 19:00","pubTimestamp":1758106800,"startTime":"0","endTime":"0","summary":"Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13M. John Volpone appointed Chief Operating Officer, in addition to his current role as President. Dr. Adam Craig, Executive Chairman, to have oversight over clinical development. BOSTON, Sept. 17, 2025  -- X4 Pharmaceuticals , a company driven to improve the lives of people with rare hematology diseases, today announced a strategic restructuring designed to sharpen operational focus and align resources with the Company's long--term strategy to successfully complete the 4WARD Phase 3 trial in patients with moderate and severe chronic neutropenia.As part of this initiative, X4 will reduce its workforce by 50%, a step anticipated to result in annualized cost savings of approximately $13 million.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","COO","LU1992135472.HKD","BK4232","BK4585","BK4139","LU2272731600.USD","LU2211815571.USD","R","XFOR","BK4022","GB00BDT5M118.USD","LU1992135399.USD","LU2272731782.SGD","BK4198"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.x4pharma.com","stockEarnings":[{"period":"1week","weight":0.01},{"period":"1month","weight":0.1099},{"period":"3month","weight":0.3074},{"period":"6month","weight":1.8252},{"period":"1year","weight":-0.7884},{"period":"ytd","weight":0.01}],"compareEarnings":[{"period":"1week","weight":0.0111},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0559},{"period":"6month","weight":0.1057},{"period":"1year","weight":0.1697},{"period":"ytd","weight":0.0111}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":-0.001295},{"month":2,"riseRate":0.625,"avgChangeRate":0.017263},{"month":3,"riseRate":0.5,"avgChangeRate":0.070477},{"month":4,"riseRate":0.25,"avgChangeRate":-0.02608},{"month":5,"riseRate":0.25,"avgChangeRate":-0.040791},{"month":6,"riseRate":0.125,"avgChangeRate":-0.268932},{"month":7,"riseRate":0.25,"avgChangeRate":-0.039863},{"month":8,"riseRate":0.375,"avgChangeRate":0.07504},{"month":9,"riseRate":0.25,"avgChangeRate":-0.001382},{"month":10,"riseRate":0.25,"avgChangeRate":-0.084011},{"month":11,"riseRate":0.25,"avgChangeRate":0.161316},{"month":12,"riseRate":0.444444,"avgChangeRate":-0.049964}],"exchange":"NASDAQ","name":"X4 Pharmaceuticals Inc","nameEN":"X4 Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"X4 Pharmaceuticals Inc(XFOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest X4 Pharmaceuticals Inc(XFOR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"X4 Pharmaceuticals Inc,XFOR,X4 Pharmaceuticals Inc股票,X4 Pharmaceuticals Inc股票老虎,X4 Pharmaceuticals Inc股票老虎国际,X4 Pharmaceuticals Inc行情,X4 Pharmaceuticals Inc股票行情,X4 Pharmaceuticals Inc股价,X4 Pharmaceuticals Inc股市,X4 Pharmaceuticals Inc股票价格,X4 Pharmaceuticals Inc股票交易,X4 Pharmaceuticals Inc股票购买,X4 Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"X4 Pharmaceuticals Inc(XFOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest X4 Pharmaceuticals Inc(XFOR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}